This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Elan Reports Second Quarter And First Half 2012 Financial Results

A reconciliation of Adjusted EBITDA from continuing operations to net loss from continuing operations, is presented in the table titled, “Unaudited Non-GAAP Financial Information – Adjusted EBITDA,” included on page 3.

Total Revenue

For the second quarter of 2012, revenue increased by 6% to $288.0 million from $270.6 million for the second quarter of 2011. For the first half of 2012, revenue increased by 11% to $576.4 million from $517.7 million for the first half of 2011.

Three Months Ended June 30
   

Six Months Ended June 30

2011

US$m
 

2012

US$m
     

2011

US$m
 

2012

US$m
  Product revenue  
183.1 211.5 Tysabri – U.S. 353.0 412.5
86.2 76.9 Tysabri – ROW 161.5 164.1
269.3 288.4 Total Tysabri 514.5 576.6
0.7 Maxipime 0.7
0.4 (0.5) Azactam 0.4 (0.5)
0.2 0.1 Royalties 2.1 0.3
270.6 288.0 Total revenue 517.7 576.4

Tysabri

Global in-market net sales of Tysabri can be analyzed as follows:

Three Months Ended June 30
   

Six Months Ended June 30

2011

US$m
 

2012

US$m

 
     

2011

US$m
 

2012

US$m
183.1   211.5 United States 353.0   412.5
205.9 184.0 ROW 385.4 382.0
389.0 395.5 Total Tysabri in-market net sales 738.4 794.5

At the end of June 2012, approximately 69,100 patients were on therapy worldwide, including approximately 31,900 commercial patients in the United States and approximately 36,400 commercial patients in the ROW, representing a 4% increase over the approximately 66,700 patients (revised) who were on therapy at the end of March 2012, and 13% over the approximately 61,200 patients (revised) who were on therapy at the end of June 2011.

2 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,630.27 +189.68 1.09%
S&P 500 2,092.67 +25.03 1.21%
NASDAQ 5,085.8170 +46.0410 0.91%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs